ClinicalTrials.Veeva

Menu

Trial of Patterned Oral Somatosensory Entrainment for Shortening Time to Oral Feeding

K

KC BioMediX

Status

Unknown

Conditions

Length of Stay
Infant, Extremely Premature
Feeding

Treatments

Device: NTrainer® Intervention
Device: Control Intervention

Study type

Interventional

Funder types

Industry

Identifiers

NCT01158391
KC_BMDX_002

Details and patient eligibility

About

The primary hypothesis is that the preterm infants (26 0/7 to 30 6/7 weeks gestational age) who undergo the NTrainer System® training will transition to full oral feeds faster than the control group (i.e. the study group will be superior to the control).

The secondary hypothesis is that the infants in the NTrainer System® experimental group will have shorter lengths of stay.

Full description

Patterned Oral Somatosensory Intervention

The interventions (Treatment vs Control) will be initiated simultaneously with tube (gavage) feeds as early as 30 weeks post-menstrual age. Before and during each training session the infant will be evaluated for the following criteria:

Criteria for Initiation of each intervention:

  1. Not on continuous vasopressor medications
  2. Feeding in previous 48 hours.
  3. Not mechanically ventilated. If the infant is on CPAP or Nasal cannula >2 liters per minute, then the FiO2 must be <40%.

Criteria for Exiting an Intervention Session:

  1. If during an intervention the baby experiences Apnea/Bradycardic/Desaturation events requiring nursing stimulation or intervention during the training--hold future interventions for one session.
  2. If the interventions are held for 3 consecutive sessions, hold interventions for a full day (24 hours).
  3. If interventions are held for 3 days (72 hours) and if GA is <32 weeks when ready to restart therapy sessions, then complete another 10 days of interventions.
  4. If interventions are held for 3 days (72 hours) and if GA is >32 weeks when ready to restart therapy, then complete the remaining N interventions sessions for a total of 10 days of therapy.
  5. If interventions are held for 3 days (72 hours) and the infant is on full oral feeds when ready to restart therapy interventions then discontinue any remaining interventions sessions.

The Interventions

Infants in the Treatment and Control group will receive orocutaneous stimulation up to four times daily during the first 30 minutes of a tube (gavage) feeding session to achieve an average of 30 therapy sessions distributed over a two week period.

Infants assigned to the either group will be offered the pacifier by gently placing the pacifier on the lips. The pacifier should not be forced into the mouth and should not be moved in any manner that would represent any form of patterned input such as moving the pacifier in and out, tapping on the lips or face or massaging the mouth or oral facial structure.

All other preparatory, infant positioning, and sampling conditions will be equal among groups. The healthcare team will continue to promote feeding and growth at the standard of care for babies in both groups.

Treatment Group

Infants in the Treatment group will receive the NTrainer System® patterned synthetic orocutaneous stimulation. A single NTrainer intervention runs for 20 minutes and involves three 3 minute sessions during which the pacifier pulses. The pulsing sessions are separated by 5.5 min breaks where the pacifier is quiet.

Control Group

Infants assigned to the control group will receive an orocutaneous intervention in which the infant will be offered a 20 minute non-nutritive sucking opportunity with a 'quiet' pacifier.

Breast Feeding Non-nutritive breastfeeding and nutritive breastfeeding practice will not be altered or changed by the interventions. The availability of the mother will be taken into consideration for the scheduling of any intervention sessions and no study intervention will interfere with breastfeeding behavior.

Safety To help ensure the safety of the study participants the heart rate, oxygen saturation, and blood pressure will be monitored throughout the therapy session.

Enrollment

210 patients

Sex

All

Ages

26 to 31 weeks old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

  • Birth Gestational age 26 0/6 - 30 6/7 weeks

Exclusion Criteria

  • Chromosomal abnormalities
  • Congenital anomalies included but not limited to
  • craniofacial malformation
  • cyanotic congenital heart disease
  • gastroschisis
  • omphalocele
  • diaphragmatic hernia or other major gastrointestinal anomalies
  • Major neurological anomaly
  • Infants with history of surgical necrotizing enterocolitis (stage III)
  • Infants with vocal cord paralysis
  • Infants with neonatal seizures
  • Infants with meningitis at time of enrollment
  • Infants who are nippling all feeds at the time of enrollment
  • Infants with narcotic abstinence syndrome (NAS)
  • Infants enrolled in another clinical study

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

210 participants in 2 patient groups

NTrainer® Intervention
Experimental group
Description:
NTrainer® Intervention - Infants in the experimental group will receive the NTrainer System patterned synthetic orocutaneous stimulation during the first 30 minutes of a tube (gavage) feeding session. The intervention may be provided up to 4 times daily to achieve an average of 30 sessions distributed over a two week period.
Treatment:
Device: NTrainer® Intervention
Control Intervention
Sham Comparator group
Description:
Control Intervention - Infants in the Control group will be provided orocutaneous stimulation with a 'quiet pacifier' during the first 30 minutes of a tube (gavage) feeding session. The intervention may be provided up to 4 times daily to achieve an average of 30 sessions distributed over a two week period.
Treatment:
Device: Control Intervention

Trial contacts and locations

5

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems